Innovate Biopharmaceuticals, Inc. announced that upon commencement of Mr. Sitar's employment, Jay P. Madan, M.S., will no longer serve as the interim principal financial officer and interim principal accounting officer of the company, but will continue to serve as the President and Chief Business Officer of the company.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | 0.00% | 0.00% | 0.00% |
Mar. 25 | North American Morning Briefing : Tech in Focus on -2- | DJ |
2023 | Bidding Procedure Approved for 9 Meters Biopharma, Inc. | CI |
1st Jan change | Capi. | |
---|---|---|
0.00% | 14 | |
+76.43% | 5.87B | |
+2.76% | 988M | |
+46.03% | 955M | |
+2.49% | 669M | |
-.--% | 600M | |
-2.15% | 593M | |
+10.28% | 536M | |
-.--% | 500M | |
-2.10% | 470M |
- Stock Market
- Equities
- NMTRQ Stock
- News 9 Meters Biopharma, Inc.
- Innovate Biopharmaceuticals, Inc. Announces Jay P. Madan, M.S., Will No Longer Serve as the Interim Principal Financial Officer and Interim Principal Accounting Officer